LinKinVax

What LinKinVax does

LinKinVax (operating as EnnoDC since the 2024 corporate refresh) is a clinical-stage biotechnology company founded in 2020 as a spin-off from the Vaccine Research Institute (VRI/Inserm/UPEC). The company is headquartered at PariSanté Campus in Paris, with a US office in Kendall Square, Cambridge, Massachusetts, and is incorporated as LINKINVAX EUROPE SAS. LinKinVax develops a dendritic cell (DC) targeting immunotherapy platform based on fully humanized CD40 partial-agonist monoclonal antibodies fused with commutable antigen tails on an engineered IgG4 backbone; this architecture is designed to prime and activate dendritic cells in vivo, generating durable antigen-specific T- and B-cell responses while avoiding Fc-related toxicity. The proprietary "DC Engager Studio" supports a pipeline of five candidates: EDC.HPVE6E7 (CD40.HVac, Phase I/IIa in HPV16-positive oropharyngeal cancer), EDC.PCA (preclinical in prostate cancer), EDC.RBDv (Phase I/II COVID-19 booster), EDC.PanCov (Phase I/II planned in 2025, pan-sarbecovirus), and CD40.HIVRI.Env (AMV.HIVRI, Phase I completed for HIV; results published in eClinical Medicine/The Lancet in October 2024).

The company's revenue model is licensing and royalties; it is pre-revenue and funded through a €31M Bpifrance public grant (May 2021), a €4.35M seed round (February 2022), and a €7.3M financing round (January 2023, including strategic investor In-Q-Tel), with a Series A of up to €50M in planning. Customer engagement is structured as clinical-trial partnerships rather than commercial sales: Phase I/IIa trials for the HPV candidate are sponsored by Gustave Roussy with Curie Institute as a second site, while ANRS MIE/Inserm sponsors the HIV and COVID-19 programs. The company holds an exclusive worldwide license from Inserm Transfert covering 13 patent families, and following a September 2024 leadership transition — Christophe Hubert as CEO, Dr. Jean-Paul Kress as Board Chairman, and Dr. Hatem Azim as CMO Oncology — LinKinVax has refocused its strategy toward oncology applications, targeting a Phase IIb in HPV16+ oropharyngeal cancer in Q2 2025 and a pre-IND filing for prostate cancer in early 2027.

Name

LinKinVax

Legal name

LINKINVAX EUROPE SAS

Website

https://ennodc.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

LinKinVax (EnnoDC) is a clinical-stage biotech developing dendritic cell-targeting antibody immunotherapies (DC engagers) for cancer and infectious diseases, with five candidates spanning HPV16+ oropharyngeal cancer, prostate cancer, COVID-19, pan-sarbecovirus, and HIV.

Ownership category

akta.pro rank

Product category

Clinical-stage immunotherapy (dendritic cell engager vaccines and cancer therapeutics)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Dendritic Cell & Other APC-based Therapies (HLAAABAF), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Dendritic cell immunotherapy
• Therapeutic cancer vaccines
• HIV vaccine development
• Monoclonal antibody platform
• CD40 targeting biologics

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Supply Chain, Operations

Revenue model

1. Not yet revenue-generating: LinKinVax/EnnoDC is a clinical-stage biotechnology company in the development phase. It has not yet commercialized any products and does not generate product revenue. The company is funded through private equity financing, public grants, and strategic investments to advance its pipeline of DC-targeting immunotherapy candidates through clinical development. Three products are in or about to enter clinical trials: a prophylactic HIV vaccine (Phase I completed), a SARS-CoV-2 vaccine (Phase I/II ongoing), and a therapeutic vaccine for HPV-related cancers (Phase I/IIa ongoing).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

LinKinVax (trading as EnnoDC) is a clinical-stage biotechnology company that designs and develops a proprietary pipeline of dendritic cell (DC) engager immunotherapies. Each DC engager is a fully humanized monoclonal antibody combining a CD40 partial-agonist head with a commutable viral or tumor antigen tail, built on an engineered IgG4 backbone to deliver antigens directly to dendritic cells in vivo. The company is advancing five candidate programs across infectious diseases (HIV, COVID-19, pan-sarbecovirus) and oncology (HPV16+ oropharyngeal cancer, prostate cancer), with three programs in active clinical trials.

Product overview

LinKinVax (trading as EnnoDC) is a clinical-stage biotech company pioneering dendritic cell-targeting immunotherapies through its proprietary DC Engager platform. The platform consists of fully humanized monoclonal antibodies combining a CD40 partial activator head for safe DC engagement with commutable tails to deliver selected viral or tumor antigens. The portfolio includes 5 DC engager candidates: EDC.HPVE6E7 (Phase I/II for HPV16+ oropharyngeal cancer), EDC.PCA (preclinical for prostate cancer), EDC.RBDv (Phase I/II for COVID-19), EDC.PanCov (Phase I/II planned for 2025 for pan-coronavirus), and CD40.HIVRI.Env (Phase I completed for HIV). The company operates from PariSanté Campus in Paris, France and Kendall Square in Cambridge, Massachusetts, USA.

Differentiator

Problem solved

Functional benefit

Brands

• DC Engagers: A novel class of immunotherapy antibodies combining a CD40 partial agonist head (for controlled DC activation) with a commutable antigen tail. The platform fuels a pipeline of 5 DC engager candidates for cancer and infectious diseases.
• AMVs (Antibody Mediated Vaccines)
• EDC.HPVE6E7
• EDC.PCA
• EDC.RBDv
• EDC.PanCov
• CD40.HVac / AMV.HPVE6E7
• CD40.HIVRI.Env / AMV.HIVRI

Products and services

• EDC.HPVE6E7 (CD40.HVac) Dendritic cell engager therapeutic vaccine targeting HPV16 E6/E7 antigens in patients with HPV16-induced oropharyngeal cancer (over 60% of head-and-neck cancer cases). Currently in Phase I/II clinical trial at Gustave Roussy and Curie Institute.
• EDC.PCA Dendritic cell engager vaccine targeting prostate cancer antigens, designed to overcome immune evasion mechanisms that have limited immunotherapy success in prostate cancer. Currently in preclinical development.
• EDC.RBDv COVID-19 vaccine candidate targeting both the ancestral Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein and a mutated version shared by several variants including Omicron, generating long-lasting T cell immunity. Currently in Phase I/II clinical trial.
• EDC.PanCov Pan-sarbecovirus vaccine targeting conserved regions of current SARS-CoV-2 variants and Sarbecoviruses plus conserved nucleocapsid antigens, designed to generate stem cell-like memory CD8 T cells for long-term protective immunity.
• CD40.HIVRI.Env (AMV.HIVRI) Prophylactic HIV vaccine candidate combining a humanized anti-CD40 monoclonal antibody fused with HIV envelope antigens to stimulate dendritic cells through CD40. Phase I ANRS VRI06 trial (NCT04842682) completed with safety and early, sustained immune responses demonstrated across 72 healthy volunteers in France and Switzerland.
• DC Engager Studio Proprietary plug-and-play platform covering T and B cell epitope mapping (selecting the most immunogenic and conserved epitopes) through clinical proof-of-concept, using a common backbone for cost-effective development of multiple DC engager candidates across solid tumors, virus-induced cancers, and viral infections.

Quantifiable outcome

• Phase I HIV vaccine trial: 100% seroconversion (antibody response) at Week 26 across all dose groups (0.3, 1, 3 mg); neutralizing antibodies detected in 50-100% of subjects by Week 26; CD4+ T cell responses remained stable until Week 48.
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Gustave Roussy Cancer CampuscoreStrategic or Co-development Partner · 19 January 2023LinKinVax and Gustave Roussy entered into a collaboration to conduct a first-in-human Phase I/IIa clinical trial with CD40HVac (EDC.HPVE6E7), a therapeutic vaccine candidate against HPV-positive oropharyngeal cancer. Gustave Roussy is the leading European cancer center (ranked 3rd globally). The study is sponsored by Gustave Roussy (EUCT N° 2022-502930-25-00 – NCT06007092) with up to 24 patients enrolled in a double-blind, randomized, placebo-controlled dose escalation trial.
• GTP BiowayscoreStrategic or Co-development Partner · 1 March 2022GTP Bioways (a CDMO - Contract Development and Manufacturing Organization) collaborated with LinKinVax to produce the first GMP batch of PanCov, a next-generation pan-sarbecovirus vaccine. GTP Bioways operates development and GMP production sites in France (Toulouse and Saint-Julien-en-Genevoix) and has a strategic partnership with FAREVA for antibody production. The collaboration enabled the first GMP batch production completed in July 2023.
• Inserm TransfertcoreOEM/ Whitelabel/ Licensing Partner · 3 February 2022Exclusive worldwide licensing agreement signed on February 3, 2022 between LinKinVax and Inserm Transfert covering industrial and commercial use of patent families related to DC-targeting technology for preventative and therapeutic vaccines against HIV, SARS-CoV-2, human papillomavirus-related cancers, and Chlamydia infections. The technology originated from the Mondor Institute for Biomedical Research (IMRB, U955 Inserm – Université Paris Est Créteil) within the Vaccine Research Institute (VRI).
• Vaccine Research Institute (VRI/Inserm/UPEC)coreStrategic or Co-development PartnerLinKinVax is a spin-off from the Vaccine Research Institute (VRI), a Laboratory of Excellence established by Inserm and Université Paris-Est Créteil in 2011. VRI provides ongoing research collaboration and the exclusive license to the DC-targeting technology. Prof. Yves Levy, founder of VRI in 2011, serves as co-founder and Chief Medical and Scientific Officer of LinKinVax/EnnoDC.
• FAREVAcoreStrategic or Co-development PartnerFAREVA, a leading French contract development and manufacturing company (turnover €2.1B, 41 production sites, 13,000 employees worldwide, head office in Tournon-sur-Rhône), contributed to the production of the PanCov next-generation COVID-19 vaccine through its partnership with GTP Bioways for GMP clinical antibody production at the Saint-Julien-en-Genevois facility.
• Curie InstitutecoreStrategic or Co-development PartnerThe Curie Institute serves as a clinical trial site alongside Gustave Roussy for the ongoing Phase I/IIa study of CD40HVac (EDC.HPVE6E7) in HPV16+ oropharyngeal cancer patients. As one of France's leading cancer research centers, Curie Institute contributes clinical site capacity for the multicenter double-blind placebo-controlled dose escalation trial.
• Baylor Institute for Immunology ResearchminorStrategic or Co-development PartnerLong-standing research partnership in dendritic cell targeting technology development. The Baylor Institute for Immunology Research (Dallas, Texas) collaborated on the original DC-targeting research that formed the basis of LinKinVax's platform, working with VRI/Inserm researchers including Prof. Zurawski and Dr. Levy.
• Moffitt Cancer CentreminorStrategic or Co-development PartnerStrategic collaboration with Moffitt Cancer Centre (Tampa, Florida, USA) in oncology. Dr. Anna Giuliano, founding Director of the Center for Immunization and Infection Research in Cancer at Moffitt, serves on EnnoDC's Scientific Advisory Committee for HPV-induced cancers.
• Paris Saclay Cancer ClusterminorStrategic or Co-development PartnerEnnoDC is one of the innovative projects selected and supported by the Paris Saclay Cancer Cluster, whose mission is to accelerate the development of innovation in oncology. Gustave Roussy is a founding member of this cluster.
• ANRS MIE / InsermcoreStrategic or Co-development PartnerANRS Emerging Infectious Diseases (autonomous agency of Inserm) sponsors and collaborates on the EDC.RBDv Phase I/II clinical trial (NCT06255626) for the COVID-19 booster vaccine. ANRS MIE previously sponsored the completed ANRS VRI06 Phase I HIV vaccine trial. ANRS MIE works in collaboration with Inserm for trial conduct and funding.
• Université Paris-Est Créteil (UPEC)coreStrategic or Co-development PartnerUPEC, alongside Inserm, established the Vaccine Research Institute (VRI) Laboratory of Excellence in 2011, which developed the DC-targeting technology. The company was founded leveraging research from U955 Mondor Institute for Biomedical Research at UPEC. Prof. Yves Levy serves as Director of VRI and holds academic affiliation with UPEC.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• BioNTech: Major mRNA vaccine and immuno-oncology company developing individualized cancer therapies and infectious disease vaccines. Comparable to LinKinVax as a European-headquartered clinical-stage-to-commercial biotech with parallel pipelines in oncology immunotherapy (HPV, prostate) and infectious disease vaccines (COVID-19, HIV), though with far greater scale and a different (mRNA) technology platform.
• Moderna: Leading mRNA therapeutics and vaccines company with an approved COVID-19 vaccine and an active oncology and infectious disease pipeline including HIV vaccine candidates. Directly comparable to LinKinVax for COVID-19 (Spikevax competitor) and HIV vaccine development, although at vastly larger scale and with proprietary mRNA technology versus LinKinVax's protein-based DC engager platform.
• Bavarian Nordic: Danish commercial-stage biotech specializing in infectious disease vaccines (mpox, smallpox, COVID-19 booster) and oncology immunotherapy (CV301 for cancer). Comparable to LinKinVax for parallel infectious disease vaccine programs including COVID-19, with broader commercial-stage scale and a different (MVA-based) platform.
• Emergent BioSolutions: U.S. specialty biopharmaceutical company developing vaccines and antibody therapeutics for infectious diseases (anthrax, smallpox, COVID-19) and emerging public health threats. Comparable to LinKinVax for the infectious disease vaccine focus and pandemic preparedness positioning, supported by IQT-relevant U.S. government contracts.

Direct peers

• CureVac: German mRNA-based vaccine and therapeutics company developing prophylactic vaccines (including COVID-19) and oncology immunotherapies. Comparable as a European-headquartered clinical-stage biotech with parallel development focus on infectious disease vaccines and oncology immunotherapies, though CureVac uses mRNA technology versus LinKinVax's DC engager approach.
• Transgene: French clinical-stage biotech developing viral-vector based immunotherapies for solid tumors (including HPV-positive cancers) and infectious diseases. Directly comparable to LinKinVax as a French clinical-stage oncology immunotherapy company targeting HPV-positive cancers, with overlapping clinical sites at Gustave Roussy and Curie Institute.

Emerging players

• ISA Pharmaceuticals: Dutch clinical-stage biotech developing therapeutic synthetic long peptide vaccines against HPV-induced cancers and other oncology indications. Comparable to LinKinVax as a niche player in HPV-positive cancer immunotherapy with a similar therapeutic vaccine mechanism and clinical stage.
• Nouscom: Clinical-stage biotech developing off-the-shelf neoantigen cancer vaccines and viral vector-based immunotherapies. Comparable to LinKinVax as a European clinical-stage immuno-oncology company developing therapeutic cancer vaccines, with overlapping target indication profiles.
• Hookipa Pharma: Austrian clinical-stage biotech developing arenavirus-based immunotherapies for infectious diseases (including HIV) and oncology. Comparable to LinKinVax as a clinical-stage vaccine/immunotherapy biotech with parallel HIV and oncology programs using a different (viral vector) technology platform.
• Inovio Pharmaceuticals: Clinical-stage biotech developing DNA-based immunotherapies and vaccines for HPV-related cancers, HIV, and infectious diseases. Comparable to LinKinVax as a clinical-stage therapeutic vaccine company with active programs in HPV-positive cancer and HIV, using a different (DNA) technology platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LinKinVax